Holden girl awaits kidney and liver transplant
Holden – 11-year old Teodora Bastug is currently on the list to receive a new kidney and a new liver after being diagnosed with β€œhyperoxaluria,” four years ago. Hyperoxaluria is a rare condition in which there is too much oxalate produced in the body ...
Community Advocate - Sat, 02 May 2015 09:52

Dicerna Announces First Quarter 2015 Financial and Operational Results
β€œIn addition, receiving Orphan Drug Designation by the U.S. Food and Drug Administration for DCR-PH1, which we announced in April 2015, was an important regulatory advancement in the development of our clinical program for Primary Hyperoxaluria Type ...
Business Wire (press release) - Mon, 11 May 2015 12:52

Dicerna Pharmaceuticals' (DRNA) CEO Douglas Fambrough on Q1 2015 ...
Seeking Alpha - Mon, 11 May 2015 19:26

Dicerna Announces Potent, Durable Knockdown of Gene Expression in Non ...
... at Dicerna, reported on experiments in non-human primates in which subcutaneous administration of DsiRNA-EX Conjugates resulted in potent and durable knockdown of HAO1, a gene implicated in the pathogenesis of primary hyperoxaluria type 1 (PH1).
Finances.com - Wed, 06 May 2015 04:35

The link between bariatric surgery and kidney stones, "Beyond the Abstract ...
We and others have documented enteric hyperoxaluria, chronic kidney disease, and calcium oxalate kidney stones are also a common and inadvertent side effect. However, the magnitude of this risk has been unclear. In the current population-based study we ...
UroToday - Thu, 14 May 2015 16:37

Allena Pharmaceuticals Announces Positive Phase 2a Data of ALLN-177 for the ...
Hyperoxaluria is excessive urinary excretion of oxalate, a condition resulting from either hyperabsorption of dietary oxalate or the overproduction of oxalate in the body due to one of several known genetic defects. Hyperoxaluria, if left untreated ...
Business Wire (press release) - Wed, 18 Mar 2015 05:22



Tekmira Pharmaceuticals' (TKMR) CEO Mark Murray on Q1 2015 Results ...
Dicerna is using our delivery technology in combination with their proprietary payload technology to develop a treatment for primary hyperoxaluria. Now, turning now to expenses, total research, development, collaborations and contracts expenses ...
Seeking Alpha - Wed, 06 May 2015 17:00

Tekmira Pharmaceuticals Corporation: Tekmira Provides Corporate Update and ...
The Wall Street Transcript - Wed, 06 May 2015 13:03

Rare Inherited Liver Disorder Therapy Granted Orphan Drug Status
Dicerna Pharmaceuticals announced that the Food and Drug Administration (FDA) has granted Orphan Drug designation to DCR-PH1 for the treatment of primary hyperoxaluria type 1 (PH1). In preclinical studies, DCR-PH1 has been shown to induce potent ...
Monthly Prescribing Reference - Fri, 24 Apr 2015 08:45

5 Stocks Under Wall Street's Radar: AbbVie Inc. (NYSE:ABBV), Apple Inc ...
Dicerna Pharma (NASDAQ: DRNA) announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to DCR-PH1, the company's therapeutic candidate for the treatment of primary hyperoxaluria type 1 (PH1). PH1 is a ...
Stock Transcript - Mon, 27 Apr 2015 05:33


1  2  3  4  5  6  7  8    ->


We do not evaluate or guarantee the accuracy of any content in this site. Click here for the full disclaimer.

Last update: September 2014